openPR Logo
Press release

Tumor Profiling Market | Ongoing Trends and Recent Developments | Major Key Players like Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US)

10-17-2019 07:51 AM CET | Health & Medicine

Press release from: MarketsandMarkets

Tumor Profiling Market | Ongoing Trends and Recent Developments

The cancer/tumor profiling market is projected to reach USD 12.47 billion by 2024 from USD 7.56 billion in 2019, at a CAGR of 10.5% during the forecast period. The increasing incidence of cancer across the globe and the increasing use of biomarkers in tumor profiling are the primary growth drivers for this market. In addition, the increase in cancer research and funding initiatives and technological advancements in profiling technologies are also propelling the growth of the cancer/tumor profiling market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1250

Opportunities:

Increasing demand for personalized medicine:

Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practice and is changing the way many diseases are identified, classified, and treated. These advancements are particularly evident in the area of oncology. According to the Personalized Medicine Coalition report (2017), the number of personalized drugs, treatments, and diagnostic products has increased since 2006, and this trend is expected to continue in the coming years. Moreover, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine over the last five years; this is further expected to increase by 33% over the next five years.

Tumor behavior is often guided by more than a single genetic or molecular marker. Rapid advances in genomic profiling of tumors have profoundly expanded knowledge of tumor behavior and guided tailored chemotherapeutic regimens for patients. The result has been a societal and clinical push toward treatment guided by personalized medicine or precision oncology. However, the progress of genomics in achieving personalized therapy is limited, owing to the inability of genetics to predict the diversity of protein expression patterns, modifications, or protein interactions following translation. Therefore, studying the proteomes of tumors and incorporating this information with genetic data has aided the advancement of personalized medicine.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1250

Tumor profiling also helps decipher which treatments are more likely to be effective, as well as those that may not be effective, which can further help identify important treatment options that might not have otherwise been considered. Thus, the growing demand for effective personalized medicine is expected to increase the adoption of tumor profiling techniques as diagnostic tools and in the drug development process, propelling the growth of the overall market.

challenges:

Low biomarker discovery-to-approval ratio:

The past two decades have witnessed significant advances in the technologies used to identify new biomarkers. Research has resulted in the identification of thousands of candidate biomarkers. Despite the advances in biomarkers in the last few years, lack of clarity regarding several basic elements restricts biomarkers from reaching their full potential in human medicine. Insufficient acceptance of robust clinical biomarker tests is one of the major challenges. Too often, biomarkers identified in initial discovery studies have not shown reproducible activity during subsequent validation. Existing biomarkers are far from comprehensive and often lack specificity, while new biomarkers are being developed at a very slow rate. This leads to the need for better biomarkers to improve diagnosis, guide molecularly targeted therapy, and monitor activity and therapeutic response for various cancer types.

The high cost involved in biomarker validation is a major concern for companies, especially small organizations. Furthermore, factors such as the inherent variability in biomarker levels (due to high diversity across the human population) and molecular heterogeneity pose additional challenges in the biomarker validation process. Another challenge is the long duration required for assay development, due to which the ability to develop assays is not keeping pace with the ability to generate biomarkers.

Read More in Detailed: https://www.marketsandmarkets.com/Market-Reports/cancer-tumor-profiling-market-1250.html

Uptake of biomarker-based tests in the clinical settings will require evidence of the biomarker’s clinical validity and utility. This is important not just to help physicians in their decision-making process within the practice of evidence-based medicine but also to achieve regulatory approval and appropriate reimbursement for the test. A better understanding of the overall process of biomarker discovery and validation and of the challenges and strategies inherent in each phase could improve the experimental study design and, in turn, increase the efficiency of biomarker development and facilitate the delivery of novel clinical tests.

Contact:

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tumor Profiling Market | Ongoing Trends and Recent Developments | Major Key Players like Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US) here

News-ID: 1851113 • Views:

More Releases from MarketsandMarkets

Laser Interferometer Market Set to Grow at the Fastest Rate- Time to Grow your Revenue
Laser Interferometer Market Set to Grow at the Fastest Rate- Time to Grow your R …
The global laser interferometer market is expected to be valued at 315 million in 2024 and is projected to reach USD 447 million by 2029, at a CAGR of 7.2% from 2024 to 2029. Emerging applications in industries push the market's growth due to the growing demand for precision in the manufacturing sector. However, challenges such as higher initial investments and maintenance costs cause problems. Despite these, opportunities arise for
With 19.6% CAGR, Battery Testing, Inspection, and Certification Market Growth to Surpass USD 36.7 billion
With 19.6% CAGR, Battery Testing, Inspection, and Certification Market Growth to …
The battery testing, inspection, and certification market is projected to reach USD 36.7 billion by 2029 from USD 14.9 billion in 2024 at a CAGR of 19.6% during the forecast period. Increasing adoption of EVs and energy storage systems, rising enforcement of stringent standards to ensure battery safety, thriving portable electronics industry, and rapid advances in battery technology are the major factors contributing to the market growth. Download PDF Brochure @
Real-Time Location Systems Revolutionize Healthcare: Insights from MarketsandMarkets
Real-Time Location Systems Revolutionize Healthcare: Insights from MarketsandMar …
The global RTLS market for healthcare is projected to grow from USD 2.3 billion in 2024 to USD 5.7 billion by 2029, at a compound annual growth rate of 19.6% from 2024 to 2029. As it attracts more and more players who enter this market with innovative RTLS features for customers, the market for RTLS technology is rapidly increasing. Top companies in this market focus on healthcare, retail, and manufacturing
Offsite Data Center Power Infrastructure Market Size to Reach $35.4 billion by 2030 | Leading key players are ABB, Schneider Electric, Eaton, Vertiv
Offsite Data Center Power Infrastructure Market Size to Reach $35.4 billion by 2 …
According to a research report "Offsite Data Center Power Infrastructure Market by Component (Solutions and Services), Vertical (BFSI, Media & Entertainment, Government & Defence, Healthcare, Manufacturing, IT & Telecom, Retail) and Region - Global Forecast to 2030" published by MarketsandMarkets, the market size for global offsite data center power infrastructure market is projected to reach approximately USD 35.4 billion by the year 2030, as compared to the estimated value of

All 5 Releases


More Releases for MarketsandMarkets™

Biomaterials Market Worth $64.2 billion | MarketsandMarkets™
Biomaterials Market in terms of revenue was estimated to be worth $45.2 billion in 2024 and is poised to reach $64.2 billion by 2029, growing at a CAGR of 7.3% from 2024 to 2029 according to a new report by MarketsandMarkets™. The biomaterials market is estimated to grow at a CAGR of 7.3% during the forecast period of 2024 to 2029. The important factors impacting market growth are the growing
Cell Expansion Market Worth $26.7 billion | MarketsandMarkets™
Cell Expansion Market in terms of revenue was estimated to be worth $14.3 billion in 2024 and is poised to reach $26.7 billion by 2029, growing at a CAGR of 13.3% from 2024 to 2029 according to a new report by MarketsandMarkets™. Some factors contributing to the growth of the global market includes increasing R&D investments in cell based research, growing focus on personalized medicine, and increasing number of strategic
Apheresis Market Worth $3.9 billion | MarketsandMarkets™
Apheresis Market in terms of revenue was estimated to be worth $2.6 billion in 2024 and is poised to reach $3.9 billion by 2029, growing at a CAGR of 8.8% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth in the apheresis market is driven by rise in demand for source plasma from biopharmaceutical companies, upsurging demand for blood components and favourable reimbursement for apheresis. The increasing
Medical Robots Market Worth $33.8 billion | MarketsandMarkets™
Medical Robots Market in terms of revenue was estimated to be worth $16.0 billion in 2024 and is poised to reach $33.8 billion by 2029, growing at a CAGR of 16.1% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth in the medical robots market is driven by the aging population and rising chronic diseases, improving reimbursement scenario, and subsequent advancements in healthcare funding & infrastructure.
Pipette Calibrators Market Worth $391 million | MarketsandMarkets™
Pipette Calibrators Market in terms of revenue was estimated to be worth $286 million in 2024 and is poised to reach $391 million by 2029, growing at a CAGR of 6.5% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by rise in genomics and proteomics research, growth in portable and handheld devices, and establishment of new research facilities by pharmaceutical
Mice Model Market Worth $2.2 billion | MarketsandMarkets™
Mice Model Market in terms of revenue was estimated to be worth $1.5 billion in 2024 and is poised to reach $2.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029 according to a new report by MarketsandMarkets™. The rise in chronic diseases, such as cancer, diabetes, and cardiovascular disorders, and growing need for reliable and predictive animal models to facilitate drug discovery and development are